Gilead acquires first TCE asset with $2.2bn Ouro Medicines buyout
Corroborated by 1 source from 1 publisher
globalgeneral3h ago
TL;DR
According to finance.yahoo.com, gilead Sciences is set to acquire Ouro Medicines for $2.2bn, marking the company’s first move into the T-cell engager (TCE) space and a deepening of ties with long-term partner, Galapagos.